Burzynski Research Institute (BZYR) Accumulated Expenses (2011 - 2025)
Burzynski Research Institute (BZYR) posted Accumulated Expenses of $24507.0 for Q4 2025, down 47.81% sequentially from $46959.0 in Q3 2025, and up 475.55% YoY from $4258.0 in Q4 2024.
Burzynski Research Institute (BZYR) Accumulated Expenses (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Accumulated Expenses for 15 years, with the latest figure at $24507.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 475.55% year-over-year to $24507.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $24507.0 (up 475.55% YoY) and the FY2025 annual result came in at $25467.0, up 38.23% from the prior year.
- Accumulated Expenses declined to $24507.0 in Q4 2025 per BZYR's latest filing, from $46959.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $58260.0 in Q2 2024 and troughed at $3091.0 in Q1 2023.
- A 5-year average of $22395.3 and a median of $15847.0 in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2024: Accumulated Expenses tumbled 91.19% in 2021, then jumped 496.02% in 2024.
- Over 5 years, Accumulated Expenses stood at $10411.0 in 2021, then gained by 13.05% to $11770.0 in 2022, then jumped by 34.64% to $15847.0 in 2023, then slumped by 73.13% to $4258.0 in 2024, then surged by 475.55% to $24507.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $24507.0, $46959.0, and $45555.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 24,507.00 |
| Aug 31, 2025 | 46,959.00 |
| May 31, 2025 | 45,555.00 |
| Feb 28, 2025 | 25,467.00 |
| Nov 30, 2024 | 4,258.00 |
| Aug 31, 2024 | 11,947.00 |
| May 31, 2024 | 58,260.00 |
| Feb 29, 2024 | 18,423.00 |
| Nov 30, 2023 | 15,847.00 |
| Aug 31, 2023 | 6,273.00 |
| May 31, 2023 | 48,609.00 |
| Feb 28, 2023 | 3,091.00 |
| Nov 30, 2022 | 11,770.00 |
| Aug 31, 2022 | 13,369.00 |
| May 31, 2022 | 30,221.00 |
| Feb 28, 2022 | 3,455.00 |
| Aug 31, 2021 | 10,411.00 |
| May 31, 2021 | 32,801.00 |
| Feb 28, 2021 | 14,287.00 |
| Nov 30, 2020 | 109,570.00 |